Effect of Atorvastatin on Fractional Flow Reserve in Coronary Artery Disease

• Status: Completed
• Trial end date: 2018-11-01
• Target enrollment: 0
• Participant gender: All

Summary

Natural course of intermediate coronary artery disease (CAD) is very important to predict the prognosis of the patient with such disease.

Several studies have well demonstrated the beneficial effect of lipid-lowering therapy on the progression of CAD with the modification of lipid profiles.

This effect can be also explained by intravascular ultrasound (IVUS) or optical coherence tomography. However, the effect of plaque modification on coronary physiology has been rarely evaluated.

This research is to evaluate the change of intermediate or nonculprit coronary lesion on lipid-lowering therapy via IVUS(optional) and FFR.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Keimyung University Dongsan Medical Center
• Collaborators: Inje University; Seoul National University Hospital; Ulsan University Hospital
• Treatments: Atorvastatin; Atorvastatin Calcium

Criteria

Inclusion Criteria:

• patient > 18 years of age and willing to participate

• patients who have stable intermediate CAD(30-80% diameter stenosis by visual estimation) on angiography with FFR≥0.8,or who have nonculprit CAD which is not planned revascularization

• Signed written Informed Consent

Exclusion Criteria:

• Patients who are in cardiogenic shock

• Patients with LVEF<35%

• Patients with left main disease, restenotic, bypass grafted lesions

• Patients with platelet count < 100,000 cell/mm3

• Patients who have co-morbidity which reduces life expectancy to one year

• Patients who have a history of stroke or transient ischemic attack within 6 months

• Patients who are planned discontinuation of medication due to surgery

• Patients with known adverse reaction to HMG CO-A reductase therapy (statins)

• Patients with liver disease (elevation of AST or ALT more than 2 times)

• Patient with creatinine > 2.0 mg/dL

• Pregnant women and women of childbearing potential who intend to have children during the duration of the trial

• Patients who consistently must take drugs affecting lipid levels in blood except the investigational product